1 unknown. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Unknown 1 |
Follow Degan Lu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody Anlotinib, Penpulimab - Lung Cancer, TKI Resistance | Phase 3 | Unknown | Degan Lu | 52 | 2023-09-01 | 2023-09-21 |
Lung Neoplasms (1)
anlotinib (1) · penpulimab (1)
PMID 27413711, PMID 28486985, PMID 29438373, PMID 30419091, PMID 33433946, PMID 33791214, PMID 34327136, PMID 35875118